Pfizer Caduet Launch Set For May; Inspra Starts Slow

Pfizer will position the Lipitor/Norvasc combination product Caduet as an "upgrade" for the vast majority of hypertension patients, rather than focus on cannibalizing Norvasc, the company told analysts during an April 20 earnings conference call

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet